tbuckley/cabot-search huggingface dataset:
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers
Authors: Frank Richard, Jan Jaap van Lier, Bernard Roubert, Teba Haboubi, Udo‐Michael Göhring, Franz Dürrenberger
Journal: American Journal of Hematology (2019)

Abstract Restriction of iron availability by ferroportin inhibition is a novel approach to treating non‐transfusion‐dependent thalassemia (β‐thalassemia intermedia). This first‐in‐human, Phase I study ( https://www.clinicaltrialsregister.eu ; EudraCT no. 2017‐003395‐31) assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of single‐ and multiple‐ascending doses (SAD and MAD) of the oral ferroportin inhibitor, VIT‐2763, in healthy volunteers. Participants received VIT‐2763 5/15/60/120/240 mg or placebo in the SAD phase and VIT‐2763 60/120 mg once daily, VIT‐2763 60/120 mg twice daily, or placebo for 7 days in the MAD phase. Seventy‐two participants completed treatment. VIT‐2763 was well tolerated and demonstrated a similar safety profile to the placebo. There were no serious or severe adverse events, or discontinuations due to adverse events. VIT‐2763 absorption was relatively fast, with detectable levels 15 to 30 minutes post‐dose. Following multiple dosing there was no apparent change in absorption and accumulation was minimal. Mean elimination half‐life was 1.9 to 5.3 hours following single dosing, and 2.1 to 3.8 hours on Day 1 and 2.6 to 5.3 hours on Day 7, following repeated dosing. There was a temporary decrease in mean serum iron levels with VIT‐2763 single doses ≥60 mg and all multiple doses; mean calculated transferrin saturation (only assessed following multiple dosing) also temporarily decreased. A shift in mean serum hepcidin peaks followed administration of all iron‐lowering doses of VIT‐2763. This effect was less pronounced after 7 days of multiple dosing (aside from with 120 mg once daily). These results support the initiation of clinical studies in patients with non‐transfusion‐dependent thalassemia and documented iron overload due to ineffective erythropoiesis.
EPID-15. GUIDELINES FOR THE OPTIMAL USE OF SOCIAL MEDIA FOR NEURO-ONCOLOGISTS
Authors: Nima Hamidi, Alireza Mansouri
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Approximately 80,000 new Americans are diagnosed with a brain tumor annually. Social media (SM) has emerged as a powerful tool for patient empowerment. Its effective utilization by healthcare professionals is vital for better connection to patients and dissemination of evidence-based information. OBJECTIVES: To develop guidelines for optimal utilization of SM by neuro-oncologists, through a review of user engagement with content posted on SM relating to brain tumors. METHODS Facebook (FB) and Twitter (TW) were searched using the term Brain Tumor. Page/account information such as user type, media (image/video) utilization in posts, and audience size (likes / followers) were recorded. Average activity and account annual growth (AAG) were calculated. Top qualitative themes were assigned. Correlations were assessed with Pearson’s test. RESULTS FB was predominantly used by organizations (64% of accounts) and provided a larger audience (67 pages,581 likes) than TW (25 accounts, 67,295 followers), which had similar proportion of personal (44%) and organizational accounts (52%). Charity &amp; Fundraising (67%) was the top FB theme. Education &amp; Research (72%) was the top TW theme. In FB, the page’s annual growth (PAG) was not related to rate of monthly posting or the length of activity on FB, but presence on other concurrent platforms (Rho: 0.59) was influential for PAG and audience size (p &lt; 0.05). In TW, quantity of monthly tweets (Rho: 0.66) and media utilization (Rho: 0.78) significantly correlated with audience size and AAG (p-values &lt; 0.05). CONCLUSION A multi-platform SM presence and use of relatable images/videos have a strong impact on both FB and TW engagement. FB is a stronger platform for organizations valuable for charity and fundraising. Multi-platform presence is more important than frequent posts on FB. TW is equally used by organizations and individuals, serving as an excellent medium for dissemination of research and educational material.
Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation
Authors: Chenglong Li, Xi Yang, Jingying Dai, Ningning Tang, Hong Zheng, Chunsen Wang, Xiaobing Huang
Journal: Blood (2019)
Unusually High Prevalence of Silent Stroke and Cerebral Vasculopathy in Hemoglobin SC Disease
Authors: Bindu K Sathi, Yoshida Yilin, Michael Raymond Weaver, Lila Wahidi Nolan, Barbara Gruner, Cara Hirner, Vinod V. Balasa, Talissa Altes, Carlos Leiva Salinas
Journal: Blood (2019)
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies
Authors: Jacqueline S Garcia, Haesook T. Kim, Jennifer Brock, Amy Han, Jeremy A. Ryan, Thelma Mashaka, Anthony G. Letai, R. Coleman Lindsley, Mahasweta Gooptu, Vincent T. Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Ilene Galinsky, Martha Wadleigh, David P. Steensma, Richard M. Stone, Robert J. Soiffer, Corey Cutler, Daniel J. DeAngelo, Joseph H. Antin
Journal: Blood (2019)
Correction: Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial
Authors: Nicolas Senn, Patricia Rarau, Danielle I. Stanisic, Leanne Robinson, Céline Barnadas, Doris Manong, Mary Salib, Jonah Iga, Nandao Tarongka, Serej Ley, Anna Rosanas-Urgell, John J. Aponte, Peter A. Zimmerman, James G. Beeson, Louis Schofield, Peter Siba, Stephen J. Rogerson, John C. Reeder, Ivo Mueller
Journal: PLoS Medicine (2012)

Background: Intermittent preventive treatment in infants (IPTi) has been shown in randomized trials to reduce malariarelated morbidity in African infants living in areas of high Plasmodium falciparum (Pf) transmission.It remains unclear whether IPTi is an appropriate prevention strategy in non-African settings or those co-endemic for P. vivax (Pv). Methods and Findings:In this study, 1,121 Papua New Guinean infants were enrolled into a three-arm placebo-controlled randomized trial and assigned to sulfadoxine-pyrimethamine (SP) (25 mg/kg and 1.25 mg/kg) plus amodiaquine (AQ) (10 mg/kg, 3 d, n = 374), SP plus artesunate (AS) (4 mg/kg, 3 d, n = 374), or placebo (n = 373), given at 3, 6, 9 and 12 mo.Both participants and study teams were blinded to treatment allocation.The primary end point was protective efficacy (PE) against all episodes of clinical malaria from 3 to 15 mo of age.Analysis was by modified intention to treat.The PE (compared to placebo) against clinical malaria episodes (caused by all species) was 29% (95% CI, 10-43, p#0.001) in children receiving SP-AQ and 12% (95% CI, 211 to 30, p = 0.12) in those receiving SP-AS.Efficacy was higher against Pf than Pv.In the SP-AQ group, Pf incidence was 35% (95% CI, 9-54, p = 0.012) and Pv incidence was 23% (95% CI, 0-41, p = 0.048) lower than in the placebo group.IPTi with SP-AS protected only against Pf episodes (PE = 31%, 95% CI, 4-51, p = 0.027), not against Pv episodes (PE = 6%, 95% CI, 224 to 26, p = 0.759).Number of observed adverse events/serious adverse events did not differ between treatment arms (p.0.55).None of the serious adverse events were thought to be treatment-related, and the vomiting rate was low in both treatment groups (1.4%-2.0%).No rebound in malaria morbidity was observed for 6 mo following the intervention.Conclusions: IPTi using a long half-life drug combination is efficacious for the prevention of malaria and anemia in infants living in a region highly endemic for both Pf and Pv.
Scaling computational genomics to millions of individuals with GPUs
Authors: Amaro Taylor-Weiner, François Aguet, Nicholas J. Haradhvala, Sager Gosai, Shankara Anand, Jaegil Kim, Kristin Ardlie, Eliezer M. Van Allen, Gad Getz
Journal: Genome biology (2019)

Abstract Current genomics methods are designed to handle tens to thousands of samples but will need to scale to millions to match the pace of data and hypothesis generation in biomedical science. Here, we show that high efficiency at low cost can be achieved by leveraging general-purpose libraries for computing using graphics processing units (GPUs), such as PyTorch and TensorFlow. We demonstrate &gt; 200-fold decreases in runtime and ~ 5–10-fold reductions in cost relative to CPUs. We anticipate that the accessibility of these libraries will lead to a widespread adoption of GPUs in computational genomics.
Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
Authors: Stefan Alig, Charles Macaulay, David M. Kurtz, Ulrich Dührsen, Andreas Hüttmann, Michael C. Jin, Brian Sworder, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joanne Soo, Florian Scherer, Alexander Craig, Olivier Casasnovas, Jason R. Westin, Gianluca Gaidano, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh
Journal: Blood (2019)
Common Myeloid Progenitors As Biomarkers of Hbf Response to Hydroxyurea in Sickle Cell Disease
Authors: Caterina P. Minniti, Seda S. Tolu, Kai Wang, Zi Yan, Andrew Crouch, Gracy Sebastian, Mark Chaitowitz, Evan Schwechter, Joan Uehlinger, Deepa Manwani, Eric Fornari, Eric E. Bouhassira
Journal: Blood (2019)
Point-of-Care Urine Pregnancy Tests
Authors: Niloofar Latifi, Gila Kriegel, A. Zara Herskovits
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NIMG-49. THE ACCURACY EVALUATION OF ARCUATE FASCICULUS OF DIFFUSION TENSOR TRACTOGRAPHY BY FUSION OF REAL SPACE AND VIRTUAL SPACE
Authors: Tsukasa Koike, Taichi Kin, Yasuhiro Takeda, Hiroki Uchikawa, Taketo Shiode, Shunsaku Takayanagi, Shota Tanaka, Nobuhito Saito
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Diffusion tensor-based tractography (DTT) is a method to estimate the direction of white matter fibers, but it is difficult to verify the relationship with brain function spatially with high accuracy. We developed a registration method to fuse the real space (brain surface photograph) and preoperative fused 3D image (virtual space) using the landmark method and thin plate spline method. In our previous study, this method was able to achieve highly accurate alignment registration error 0.7±0.1mm (mean±SE) even after brain shift due to craniotomy. In this study, we proposed a method to examine spatial errors of DTT and direct cortical stimulation (DCS) and verify its accuracy. METHODS We included 7 gliomas performed awake surgery. We created the fused three – dimensional image before surgery and acquired the brain surface photograph immediately after craniotomy, then we aligned them using the proposed method. Sites that showed speech arrest by DCS were plotted on the fused image. A circle with a radius of 15 mm centered on the same site was taken as the range over which the current spreads. The surface area of each of the circles was calculated to make it true if there was arcuate fasciculus drawn with DTT in the circle, and false if it did not exist. By using this method, the accuracy of the DTT was verified. RESULT: In 7 cases, speech arrest was shown at 21 DCS plots. The probability of the presence of DTT within the current spread of DCS was 64.4%. CONCLUSION The proposed method indicates that DTT does not necessarily match the DCS results by verification using real space and virtual space. We present some illustrative cases.
Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination
Authors: Athanasios Papadas, Evan Flietner, Zachary Morrow, Joshua Wiesner, Alexander Cicala, Adam Pagenkopf, Chelsea L. Hope, Adhithi Rajagopalan, Zhi Wen, Philip Emmerich, Dustin Deming, Shigeki Miyamoto, Peiman Hematti, Natalie Scott Callander, Alexander Rakhmilevich, Mario Otto, Christian M. Capitini, Jing Zhang, Fotis Asimakopoulos
Journal: Blood (2019)
Oral Contraceptives and Liver Damage
Authors: B. A. Stoll, J. T. Andrews, R. Motteram, J. Upfill
Journal: BMJ (1965)

Aetiology of Multiple SclerosisSIR,-By using a new method, recently referred to in your columns1 by Sir Macfarlane Burnet, we find that suspected idiopathic autoimmune disorders can be classified by statistical criteria into two categories.This division also corresponds, interestingly enough, to a fundamental anatomical distinction regarding the location of the target tissue.
KIR-Genotype Mismatch, Donor KIR Locus 3DS1 Positive or 2DS3 Negative Facilitates a Positive Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study of 74 Patients
Authors: Yu Zhang, Shaozhen Chen, Jinhua Ren, Xiaofeng Luo, Jianda Hu, Ting Yang
Journal: Blood (2019)
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
Authors: Irene Catalano, Elena Grassi, Andrea Bertotti, Livio Trusolino
Journal: Trends in cancer (2019)

HighlightsDifferent mutational burden only partially explains the different response of MSI and MSS CRCs to immunotherapy.Neoantigen load, as measured using available prediction algorithms, is not sufficiently accurate for implementation into clinical decision making.Abundant immune infiltration in the tumor tissue is likely to have high prognostic value, but not an equally high predictive value in terms of response to immunotherapy.The intrinsic characteristics of MSI and MSS CRCs determine differences in their evolutionary paths, which inevitably influence the way the immune system sculpts tumor clonal and subclonal dynamics.AbstractImmunotherapy with immune checkpoint inhibitors is an approved treatment option for a subpopulation of patients with colorectal cancers that display microsatellite instability. However, not all individuals within this subgroup respond to immunotherapy, and molecular biomarkers for effective patient stratification are still lacking. In this opinion article, we provide an overview of the different biological parameters that contribute to rendering colorectal cancers with microsatellite instability potentially sensitive to immunotherapy. We critically discuss the reasons why such parameters have limited predictive value and the implications therein. We also consider that a more informed knowledge of response determinants in this tumor subtype could help understand the mechanisms of immunotherapy resistance in microsatellite stable tumors. We conclude that the dynamic nature of the interactions between cancer and immune cells complicates conventional biomarker development and argue that a new generation of adaptive metrics, borrowed from evolutionary genetics, may improve the effectiveness and reliability of clinical decision making.
Nabil Nassar: physician, teacher, and editor in chief of the Middle East edition of <i>The BMJ</i>
Authors: Rebecca Wallersteiner
Journal: BMJ (2019)

Photo credit: American University of Beirut

Nabil Nassar, who has died at the age of 80, enjoyed a dual career as a physician and teacher at the American University of Beirut (AUB) and as the innovative editor in chief of the Middle East edition of The BMJ for nearly 20 years.

Apart from international postings at universities—including Stanford, Harvard, and the London Hospital for Tropical Diseases—Nassar spent much of his career at AUB, from his student days in the 1960s to retirement. He graduated from AUB with a bachelor of science in 1961 and qualified in medicine in 1965. The Beirut of Nassar’s youth was a cosmopolitan city, nicknamed the “Paris of the Middle East” thanks to its French influences and vibrant cultural and intellectual life. It was one of the most exciting places around the world to be a student.

Fuad Ziyadeh, chair of the department of internal medicine at AUB, a close friend and colleague of Nassar’s, recalled: “A consummate professional and stalwart of AUB and its medical centre for most of his life, Dr Nassar was beloved among his students and patients and was greatly admired for his exemplary service, gentle manner, …
Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
Authors: Sameem Abedin, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C. Michaelis, Ehab L. Atallah, Mehdi Hamadani, Alexandra M. Harrington, Karen Carlson
Journal: Blood (2019)
The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation
Authors: Guo-Pan Yu, Zhao Yin, Zhiping Fan, Fen Huang, Na Xu, Ling Jiang, Zhixiang Wang, Li Xuan, Qifa Liu, Ru Feng, Jing Sun
Journal: Blood (2019)
Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC
Authors: Bae P Chu, Neeta Pandit-Taskar, Boglarka Gyurkocza, Qing Liang, Daniel Miodownik, Vijay Reddy, Mark S. Berger, Lawrence T. Dauer
Journal: Blood (2019)
IMMU-40. CANCER IMMUNOEDITING SHAPES THE IMMUNE ESCAPE SIGNATURE AND CLONAL ARCHITECTURE IN GLIOMAS
Authors: Katrin Lamszus, Malte Mohme, Cecile Maire, Kristoffer Riecken, Malik Alawi, Boris Fehse, Manfred Westphal
Journal: Neuro-Oncology (2019)

Abstract Immunotherapeutic strategies are increasingly important in neuro-oncology, and the elucidation of escape mechanisms which lead to treatment resistance is crucial. Understanding heterogeneous clonal dynamics and emergence of immune escape variants during cancer immunoediting can yield valuable insights into the adaptive processes governing treatment resistance. We applied a recently developed multicolor labeling strategy termed optical barcoding to compare in vivo clonality in an immunocompetent vs immunodeficient environment. Optically barcoded GL261 glioma cells were implanted in parallel into the brains of i) wildtype (wt) C57BL/6 mice, ii) immunodeficient Pfp-/- Rag2-/- mice or iii) PD1-/- mice and tumor growth was monitored. Ex vivo analysis of individual tumor clones revealed that tumors in immunocompetent mice had a profoundly different clonal architecture compared to immunodeficient mice. Whereas tumors in pfp-/- rag2-/- mice exhibited a highly polyclonal composition, immunoedited tumors in wt and PD1-/- mice showed reduced clonality with emergence of immune escape clones, independent of in vitro proliferation rates. Survival of wt mice was significantly longer than of Pfp-/- Rag2-/- mice and was even more prolonged in PD1-/- mice. Immunoediting in immunocompetent mice was further associated with striking differences in vascularity and invasiveness. Time-course microarray analyses, flow-cytometric phenotyping of tumor-infiltrating immune cells and immunostaining highlighted the role of PD-L1 and other immunosuppressive mediators as mechanisms to adapt to T-cell infiltration and IFN-ɣ production. Furthermore, RNAseq profiling of FACS-separated tumor cells, T cells and macrophages/microglia allowed the identification of IFN-ɣ-mediated T-cell-shaped gene expression signatures and of new pathways potentially involved in the immune escape of gliomas. To conclude, the process of cancer immunoediting during tumor evolution not only shapes gene expression profiles and growth patterns, but also has a profound impact on the intratumoral clonal heterogeneity in malignant gliomas.
Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany
Authors: Carl C. Crodel, Kathleen Jentsch-Ulrich, Lutz Jacobasch, Philipp Kiewe, Jens Kisro, Jörg Lipke, Siegfried W. Prenninger, Marcel Reiser, Regine Wunschel, Andreas Hochhaus, Florian H. Heidel
Journal: Blood (2019)
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Noopur S. Raje, Andrzej Jakubowiak, Cristina Gasparetto, Robert F. Cornell, Heike I. Krupka, Daniel Navarro, Alison J. Forgie, Chandrasekhar Udata, Cynthia Basu, Jeffrey Chou, Abraham Leung, Alexander M. Lesokhin
Journal: Blood (2019)
Challenging the Association of Marijuana Laws With Teen Marijuana Use
Authors: Mary Cannon
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Is Variance Ratio a Valid Indicator of Heterogeneous Treatment Effect?—Reply
Authors: Stephanie Winkelbeiner, Philipp Homan
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal